Tumour regression & tissue repair when ZOL is combined with IFO in rat osteosarcoma

Aim: To evaluate the efficacy of the combination of zoledronic acid (ZOL) with ifosfamide (IFO) on local tumor growth, histologic response, and animal survival using a rat-transplantable model of osteosarcoma.

Conclusions: This is the first report of the anti-bone resorption and antitumoral activities of zoledronic acid in a rat model of osteosarcoma, and its beneficial association with an antitumoral chemotherapeutic drug in preventing tumor recurrence.

Official Title

Enhanced tumour regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma

Conditions

Study Type

Experimental using a rat-transplantable model

Study Design

Treatment: Zoledronic acid (disodium hydrate 20L) 100 ug/kg s.c. twice weeklyIfosfamide (IFO) 15 mg/kg i.p. d20, 21, 22 after tumor implantation.

Further Details

Efficacy:Tumor volume was reduced by IFO, with complete regression 12 days after IFO injection (3 x 15 mg/kg) in 50-75% cases, but tumor recurrence was observed 22 days after IFO injections.Treatment with ZOL was effective in preventing the formation of osteolytic lesions and in reducing the local tumor growth.The combination of ZOL and IFO was more effective than each agent alone in preventing tumor recurrence, improving tissue repair and increasing bone formation.

Study Start

Eligibility & Criteria

Indication: Osteosarcoma

Total Enrolment

Contact Details

Heymann,D.; Ory,B.; Blanchard,F.; Heymann,M.F.; Coipeau,P.; Charrier,C.; Couillaud,S.; Thiery,J.P.; Gouin,F.; Redini,F.Instiution: Medicine Faculty of Nantes, Nantes, FranceBone 37 (2005): 74-86